ES2175842T3 - Antagonistas de kv2.1. - Google Patents

Antagonistas de kv2.1.

Info

Publication number
ES2175842T3
ES2175842T3 ES98964497T ES98964497T ES2175842T3 ES 2175842 T3 ES2175842 T3 ES 2175842T3 ES 98964497 T ES98964497 T ES 98964497T ES 98964497 T ES98964497 T ES 98964497T ES 2175842 T3 ES2175842 T3 ES 2175842T3
Authority
ES
Spain
Prior art keywords
antagonists
methods
assays
identifying
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98964497T
Other languages
English (en)
Inventor
Dulce Garrido Bubacz
Iain David Dukes
Ed Williams Mclean
Robert Anderson Noe
Andrew James Peat
Jerzy Ryszard Szewczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2175842T3 publication Critical patent/ES2175842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1. Uso de un compuesto de fórmula (1) o una sal o solvato farmacéuticamente aceptable del mismo **fórmula** en la que R representa alquilo C1-12, alquenilo C1-12, -CyH2y-R 7 o -CyH2y-O-R 7 ,siendo y un número entero de 1-6 y R 7 es hidrógeno, alquilo C1-6 cicloalquilo C3-7, cicloalquenilo C4-7 o un imidazolidinilo, piperidilo, piperazinilo, pirrolidinilo, morfolinilo, piridilo, piridazinilo, pirimidinilo, pirazinilo, pirrolilo, pirazolilo, imidazolilo, piranilo, furilo, tienilo, oxazolilo, isoxazolilo, oxadiazolilo, tiazolilo, tiadiazolilo, triazolilo o tetrazolilo sustituido o no sustituido, o R representa -CyH2y-R 9 , -CyH2y-O-R 9 o -CyH2y-OCH2-R 9 , siendo y independientemente como se ha definido anteriormente y R 9 es siendo R4 hidrógeno o halógeno, y representando independientemente R5 y R6 hidrógeno, halógeno, -Oalquilo C1-3, oR5 y R6 pueden forman conjuntamente un anillo metilendioxi o etilendioxi; R1 representa siendo cada R8 independientemente hidrógeno, halógeno, -O-alquilo C1-3,alquilo C1-3, uoroalquilo C1-3 o -C(O)-R 9 , siendo R 9 alquilo C4-8 o cicloalquilo C3-7; X representaO,SoN-R 2 , estando defiido R 2 independientemente como anteriormente para R; y R 3 representa H o alquilo C1-3, en la fabricación de un medicamento para el tratamiento de la diabetes no insulino-dependiente.
ES98964497T 1997-12-18 1998-12-16 Antagonistas de kv2.1. Expired - Lifetime ES2175842T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726630.8A GB9726630D0 (en) 1997-12-18 1997-12-18 Kv2.1 Antagonists

Publications (1)

Publication Number Publication Date
ES2175842T3 true ES2175842T3 (es) 2002-11-16

Family

ID=10823738

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98964497T Expired - Lifetime ES2175842T3 (es) 1997-12-18 1998-12-16 Antagonistas de kv2.1.

Country Status (9)

Country Link
US (1) US6589934B1 (es)
EP (1) EP1042322B1 (es)
JP (1) JP2001526289A (es)
AT (1) ATE216386T1 (es)
AU (1) AU1967199A (es)
DE (1) DE69805002T2 (es)
ES (1) ES2175842T3 (es)
GB (1) GB9726630D0 (es)
WO (1) WO1999032487A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60203007T2 (de) * 2001-06-01 2005-07-07 Neurosearch A/S Heteroaryl-diazabicycloalkanderivaten als cns-modulatoren
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
CN112294835B (zh) * 2019-11-15 2021-09-17 南通大学 LncRNA-266在制备诱导棕色脂肪细胞分化药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU184960B (en) * 1981-07-20 1984-11-28 Richter Gedeon Vegyeszet Process for preparing new derivatives of 3,7-diazabicyclo/3.3.1/ nonane
US5158969A (en) * 1991-08-21 1992-10-27 Neurosearch A/S Indole derivatives as potassium channel blockers
US5559009A (en) * 1994-03-04 1996-09-24 The Regents Of The University Of California Voltage-gated potassium channel gene, KV1.7, vectors and host cells comprising the same, and recombinant methods of making potassium channel proteins
HUT75093A (en) * 1995-01-20 1997-04-28 Richter Gedeon Vegyeszet New anti-radical pharmaceutical compositions and process for producing them
EP0891347A4 (en) * 1995-10-31 1999-04-07 Merck & Co Inc Triterpene derivatives with immunosuppressant activity

Also Published As

Publication number Publication date
EP1042322B1 (en) 2002-04-17
US6589934B1 (en) 2003-07-08
AU1967199A (en) 1999-07-12
DE69805002D1 (de) 2002-05-23
ATE216386T1 (de) 2002-05-15
JP2001526289A (ja) 2001-12-18
WO1999032487A1 (en) 1999-07-01
DE69805002T2 (de) 2002-11-21
GB9726630D0 (en) 1998-02-18
EP1042322A1 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
DE69626660D1 (en) 2-alkylpyrrolidine
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
GEP20105118B (en) Anti-vegf antibodies
ID23374A (id) Halogenopirimidin
AU9386398A (en) Cysteine rich receptors: trail
DE69625926D1 (de) Absorbierende zusammensetzung und saugfähiges wegwerfkleidungsstück, welches dasselbe enthält
BR9810654B1 (pt) mÉtodo de preparaÇço de um polipeptÍdeo, molÉculas de anticorpo e composiÇço.
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
IL137178A0 (en) Il-18 receptors
GB9818916D0 (en) Use
AR016981A2 (es) Polipeptidos sinteticos
EP1412388A4 (en) HUMANIZED ANTIBODIES DERIVED FROM DD-3B6 / 22, SPECIFIC OF THE FIBRIN D-DIMER FRAGMENT
EA200000519A1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
ZA200006080B (en) Human BMP-7 promoter and method for exploring bone-related substance by using the same.
EA199800867A1 (ru) Соединения тетрагидробетакарболина
ZA98755B (en) Substituted hydroxy-anilino derivatives of cyclobutane-3,4-diones.
ES2175842T3 (es) Antagonistas de kv2.1.
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
AU5999199A (en) Novel antibodies, drugs containing these antibodies and methods for screening compounds by using these antibodies
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
AU2205099A (en) Chimeric proteins for the treatment of diabetes
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
TR199700547A2 (xx) N-asetonilbenzamid fungisitler.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1042322

Country of ref document: ES